Clinical Trials Sponsored by PharmaLogic Development, Inc

Total 1125 results

Glaucoma Research & Education Group
PharmaLogic Development, Inc.

Unknown

The Efficacy of Selective Laser Trabeculoplasty

Primary Open Angle Glaucoma | Ocular Hypertension | Pigment Dispersion Glaucoma | Pseudo-Exfoliative Glaucoma

United States
Glaucoma Research & Education Group
PharmaLogic Development, Inc.

Completed

Effectiveness of a Procedure for Previously Failed Glaucoma Surgery

Glaucoma

United States
Xilio Development, Inc.

Recruiting

XTX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Xilio Development, Inc.

Active, not recruiting

XTX202 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Eisai Inc.
PharmaBio Development Inc.

Terminated

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Rectal Cancer | Colon Cancer

Argentina, Russian Federation, United States, Australia, Brazil, Ukraine
Eisai Inc.
PharmaBio Development Inc.

Terminated

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Ovarian Cancer

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Belgium, Italy, Spain, United States, Ukraine, United Kingdom
Eisai Inc.
PharmaBio Development Inc.

Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Bladder Cancer

United Kingdom, Netherlands, Spain, Germany, United States, Ukraine
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
Sunovion Respiratory Development Inc.

Completed

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7)

COPD

United Kingdom
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Education Development Center, Inc.

Completed

Reducing HIV Risks in African American Teens

HIV Infections

United States
Centocor Research & Development, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (PHOENIX1)

Psoriasis

United States, Belgium, Canada
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Sunovion Respiratory Development Inc.

Completed

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

COPD

United States
Sunovion Respiratory Development Inc.

Completed

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (GOLDEN-4)

Chronic Obstructive Pulmonary Disease | COPD

United States
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
C.T. Development America, Inc.

Completed

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

Amyloidosis

Spain, United States, Italy, Belgium, Netherlands, India, Tunisia, Latvia, Turkey, France, Germany, Estonia, Lithuania, Poland, Russian Federation, Georgia, United Kingdom, Israel, Egypt, Finland, Peru, Sweden, Ukraine
C.T. Development America, Inc.

Completed

A Study of RX-10045 in the Treatment of Dry Eye Disease

Dry Eye Syndrome

United States
C.T. Development America, Inc.

Completed

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Education Development Center, Inc.

Completed

Parent Education for Young Teen Females

Prevention

United States
Labcorp Drug Development Inc

Recruiting

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine (PREFER)

Melanoma | Soft Tissue Sarcoma | Stomach Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Rhabdomyosarcoma | Uterine Cancer

United States
Sunovion Respiratory Development Inc.

Completed

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease (COPD)

United States
Sunovion Respiratory Development Inc.

Completed

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-3)

COPD

United States
Sunovion Respiratory Development Inc.

Completed

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-5)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Czechia, Hungary, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Belgium, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Education Development Center, Inc.

Unknown

Addressing Proven Factors in HIV Prevention for Latino Youth

HIV | Sexually Transmitted Infections
Aurinia Pharmaceuticals Inc.
Labcorp Drug Development Inc

Recruiting

Voclosporin in Adolescents With Lupus Nephritis (VOCAL)

Adolescent Lupus Nephritis

United States
Otsuka Pharmaceutical Development & Commercialization...
Quintiles, Inc.

Completed

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (EQUATOR)

Acute Schizophrenia

United States, Malaysia, Serbia, Ukraine, Romania, Puerto Rico, Colombia, Turkey
Alimentiv Inc.
Takeda Development Center Americas, Inc.

Recruiting

Determination of the Optimal Treatment Target in Ulcerative Colitis (VERDICT)

Colitis, Ulcerative

Canada, United Kingdom, Poland, Italy, United States, Belgium, France, Netherlands, Belarus, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy

United States
COUR Pharmaceutical Development Company, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

Neurobehavioral Disinhibition

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

Binge-Eating Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Attention-deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder (STEP-A)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

Agitation in Participants With Dementia of the Alzheimer's Type

United States, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

Intermittent Explosive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

Adult Attention-deficit Hyperactivity Disorder (ADHD)

Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Atopic Dermatitis

Poland, United States, Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

Finland, Germany, Korea, Republic of, United States, Taiwan, Estonia, India, Italy, Mexico

3

Subscribe